Experimental drugs from Roche and Eli Lilly failed to halt Alzheimer’s disease in their latest test, the companies said on Monday, in a blow to people whose genes make them particularly vulnerable to the illness. Pursuit of an Alzheimer’s remedy, which would inevitably reap drugmakers billions of dollars, has been marked by more than 100 failures, although researchers still hope to tame a condition that affects nearly 6 million Americans, more than 40 million people worldwide, and which is growing more prevalent. The study of Roche’s gantenerumab and Eli Lilly’s solanezumab spearheaded by Washington University in St. Louis …read more
Source:: Yahoo Finance
